Benzinga | Jan 11, 2022 07:31AM EST

Institutional Review Board Grants Approval For Cybin-Sponsored Feasibility Study Using Kernel Flow Technology To Measure Psychedelic Effects On The Brain

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(tm)", today announced that an Institutional Review Board ("IRB") has approved a Company-sponsored feasibility study using Kernel's quantitative neuroimaging technology, Kernel Flow, to measure ketamine's psychedelic effect on cerebral cortex hemodynamics.

As part of Cybin's sponsorship of the feasibility study, the Company will retain an exclusive interest in any innovations that are discovered or developed through its independent analysis of the study findings.

"By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting," said Doug Drysdale, Cybin's Chief Executive Officer. "We believe the results of this study will lead to future studies that will test the effectiveness of psychedelic treatments and will further support our mission to develop psychedelics into therapeutics."

The study received U.S. Food and Drug Administration ("FDA") Investigational New Drug ("IND") authorization in October 2021 and is expected to begin enrollment in early 2022.